Compare · ARA vs PGNY
ARA vs PGNY
Side-by-side comparison of American Renal Associates Holdings, Inc (ARA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY carries a market cap of $2.07B.
- PGNY has hit the wire 7 times in the past 4 weeks while ARA has been quiet.
- PGNY has more recent analyst coverage (25 ratings vs 0 for ARA).
- Company
- American Renal Associates Holdings, Inc
- Progyny Inc.
- Price
- -
- $27.10+0.41%
- Market cap
- -
- $2.07B
- 1M return
- -
- +6.23%
- 1Y return
- -
- +20.36%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- 2019
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest ARA
- SEC Form 15-12B filed
- SEC Form EFFECT filed
- SEC Form SC 13G/A filed
- SEC Form 4 filed by P L Partners Capital Centerbridge
- SEC Form 4: W Thomas Erickson disposed to the issuer $0 worth of Common Stock (67,755 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: J Christopher Hocevar disposed to the issuer $0 worth of Common Stock (18,679 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: A Joseph Carlucci disposed to the issuer $0 worth of Common Stock (1,245,164 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: M John Jureller disposed to the issuer $0 worth of Common Stock (49,435 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: T Syed Kamal disposed to the issuer $0 worth of Common Stock (1,291,236 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: Victoria Labriola disposed to the issuer $0 worth of Common Stock (64,569 units at $0.00), decreasing ownership by 100% to 0 units
Latest PGNY
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.66% to 72,453 units (SEC Form 4) (withholding tax)
- Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares, decreasing direct ownership by 2% to 81,026 units (SEC Form 4) to satisfy withholding tax
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.